Inhibikase Therapeutics Q3 EPS $(0.13), Inline

Inhibikase Therapeutics -0.66% Pre

Inhibikase Therapeutics

IKT

1.50

1.50

-0.66%

0.00% Pre
Inhibikase Therapeutics (NASDAQ: IKT) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 80 percent increase over losses of $(0.65) per share from the same period last year.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via